New Target To Stop Cancer’s Spread Discovered By Georgia State University Scientists
News Feb 04, 2013
Cell migration is essential for the spread of cancerous cells, also known as metastasis, as well as for other diseases. The research team in the labs of Zhi-Ren Liu, professor of biology, and Jenny Yang, professor of biochemistry, studied the interaction of two molecules, p68 RNA helicase and calcium-calmodulin.
Interrupting the interaction between p68 and calcium-calmodulin, which is essential for cell migration, inhibited metastasis.
The findings were recently published in Nature Communications.
“Cancer, at its primary site, will not necessary kill,” Liu explained. “Cancer kills by multi-site metastasis. If we are able to disrupt this interaction, we will able to inhibit cancer metastasis. The research indicates that the interaction is absolutely required for all cell migration, and we suspect it may not be limited to cancerous-type cells. It may be a general phenomenon for all cell types.”
Calcium-calmodulin is an important protein, acting like a messenger to turn different proteins on and off, said Yang, whose lab focuses on calcium’s role in biological processes.
“Calmodulin is a very interesting protein and it interacts with many different systems in response to calcium level changes,” she said. “We have demonstrated a new target. There are new ways possible to modulate calcium signaling as a way to treat diseases.”
Because cell migration is a common phenomenon that is not only normal, but also related to diseases, there are impacts on treating other diseases, Liu said, from inflammation to neurodegenerative diseases and heart disease.
Bioinformatics to Help Understand Intrinsically Disordered ProteinsNews
Over the last several decades, scientists have sequenced 85 million unique proteins, structured and unstructured alike, but still don’t know what the vast majority of these proteins do.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018